Literature DB >> 23158804

Effectiveness of early medical abortion using low-dose mifepristone and buccal misoprostol in women with no defined intrauterine gestational sac.

Philip Goldstone1, Jill Michelson, Eve Williamson.   

Abstract

BACKGROUND: The study was conducted to assess the effectiveness of early medical abortion (EMA) in women with early pregnancy and no defined intrauterine gestational sac (IUGS) on ultrasound. STUDY
DESIGN: Retrospective, multicenter, observational study of oral mifepristone 200 mg and buccal misoprostol 800 mcg administered 24-48 h later for EMA (gestations ≤ 63 days). Odds ratios (ORs) [95% confidence intervals (CIs)] of EMA failure and continuing pregnancy for women with no defined IUGS vs. those with confirmed IUGS were calculated.
RESULTS: Women with no defined IUGS were more likely to experience EMA failure [9.0% (6/67) vs. 3.5% (465/13,345); OR (95% CI)=2.72 (1.17-6.33), p=.041] and continuing pregnancy [7.5% (5/67) vs. 0.6% (83/13,345); OR (95% CI)=12.72 (4.98-32.46), p<.001].
CONCLUSION: EMA failure is more likely in women with early pregnancy and no defined IUGS than those with gestations ≤ 63 days and confirmed IUGS.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23158804     DOI: 10.1016/j.contraception.2012.10.013

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location.

Authors:  Alisa B Goldberg; Isabel R Fulcher; Jennifer Fortin; Rebecca K Hofer; Alex Cottrill; Divya Dethier; Allison Gilbert; Elizabeth Janiak; Danielle Roncari
Journal:  Obstet Gynecol       Date:  2022-04-05       Impact factor: 7.623

2.  Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond.

Authors:  Elizabeth G Raymond; Daniel Grossman; Alice Mark; Ushma D Upadhyay; Gillian Dean; Mitchell D Creinin; Leah Coplon; Jamila Perritt; Jessica M Atrio; DeShawn Taylor; Marji Gold
Journal:  Contraception       Date:  2020-04-16       Impact factor: 3.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.